undefined undefined undefined

Relative efficacy of tafamidis, acoramidis, patisiran and vutrisiran in patients with transthyretin cardiac amyloidosis: a network meta-analysis

Event: ESC Congress 2025

Topic: Infiltrative Myocardial Disease

Session: Treatment of transthyretin amyloidosis

Access

Like

Plasma transthyretin fractions in transthyretin cardiac amyloidosis patients undergoing tafamidis treatment

Event: ESC Congress 2025

Topic: Infiltrative Myocardial Disease

Session: Shedding light on transthyretin cardiac amyloidosis

Access

Like

Cardiac remodelling and sympathetic activation in cardiac amyloidosis: insights from transcardiac blood sampling

Event: ESC Congress 2025

Topic: Infiltrative Myocardial Disease

Session: Cardiac amyloidosis (2)

Access

Like

Relative efficacy of tafamidis, acoramidis, patisiran and vutrisiran in patients with transthyretin cardiac amyloidosis: a network meta-analysis

Event: Heart Failure 2025

Topic: Pharmacotherapy

Session: Evolving treatment paradigms in heart failure: from SGLT2 inhibition to transthyretin stabilisation and beyond

Access

Like

Chest pain after elective percutaneous coronary intervention as trigger of Takotsubo syndrome

Event: ESC Congress 2024

Topic: Clinical

Session: Takotsubo syndrome

Access

Like

Incidence and clinical characteristics of cardiac amyloidosis in Tuscany and Umbria

Event: ESC Congress 2024

Topic: Infiltrative Myocardial Disease

Session: The different faces of cardiac amyloidosis

Access

Like

Biohumoral and echocardiographic correlates of tafamidis treatment in transthyretin cardiac amyloidosis

Event: Heart Failure 2023

Topic: Clinical

Session: Novelties in amyloid cardiomyopathy

Access

Like

Prognostic value of sST2 in heart failure patients with diabetes

Event: Heart Failure 2021

Topic: Biomarkers

Session: ePoster session

Access

Like

High-sensitivity cardiac troponin T and NT-proBNP for ruling-in and ruling-out of cardiac amyloidosis

Event: ESC Congress 2020

Topic: Infiltrative Myocardial Disease

Session: Advances in the Diagnosis and Treatment of Cardiac Amyloidosis

Access

Like

Biopsy evidence of dual amyloidosis in the same patient: diachronous cardiac involvement by transthyretin and immunoglobulin light chains.

Event: ESC Congress 2020

Topic: Clinical

Session: Amyloidosis

Access

Like

undefined undefined undefined

Contributor content

Relative efficacy of tafamidis, acoramidis, patisiran and vutrisiran in patients with transthyretin cardiac amyloidosis: a network meta-analysis

Plasma transthyretin fractions in transthyretin cardiac amyloidosis patients undergoing tafamidis treatment

Cardiac remodelling and sympathetic activation in cardiac amyloidosis: insights from transcardiac blood sampling

Relative efficacy of tafamidis, acoramidis, patisiran and vutrisiran in patients with transthyretin cardiac amyloidosis: a network meta-analysis

Chest pain after elective percutaneous coronary intervention as trigger of Takotsubo syndrome

Incidence and clinical characteristics of cardiac amyloidosis in Tuscany and Umbria

Biohumoral and echocardiographic correlates of tafamidis treatment in transthyretin cardiac amyloidosis

Prognostic value of sST2 in heart failure patients with diabetes

High-sensitivity cardiac troponin T and NT-proBNP for ruling-in and ruling-out of cardiac amyloidosis

Biopsy evidence of dual amyloidosis in the same patient: diachronous cardiac involvement by transthyretin and immunoglobulin light chains.

ESC 365 is supported by